{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:38Z","timestamp":1791979118649,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Hangzhou Health Science and Technology Planning Project","award":["OO20190083"],"award-info":[{"award-number":["OO20190083"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jgar.2019.10.008","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T19:31:23Z","timestamp":1571340683000},"page":"235-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Changcheng","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.10.008_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0010","series-title":"Antibiotic resistance threats in the United States, 2013","author":"CDC","year":"2013"},{"key":"10.1016\/j.jgar.2019.10.008_bib0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2019.10.008_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/430909","article-title":"Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis","volume":"41","author":"DiazGranados","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/ice.2015.228","article-title":"VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis","volume":"37","author":"Prematunge","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2019.10.008_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2016.06.010","article-title":"Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis","volume":"48","author":"Zhao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.10.008_bib0035","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/14787210.2015.1001839","article-title":"Therapeutic options for vancomycin-resistant enterococcal bacteremia","volume":"13","author":"Barber","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2019.10.008_bib0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14787210.2.1.51","article-title":"A review of linezolid: the first oxazolidinone antibiotic","volume":"2","author":"Stevens","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2019.10.008_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijantimicag.2014.08.002","article-title":"Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci","volume":"44","author":"Munita","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.10.008_bib0055","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01289-13","article-title":"Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia","volume":"58","author":"Balli","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-014-0687-9","article-title":"Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0065","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.00714-13","article-title":"Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections","volume":"57","author":"Whang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jgar.2019.10.008_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2015.11.005","article-title":"Towards a definition of daptomycin optimal dose: lessons learned from experimental and clinical data","volume":"47","author":"Senneville","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2019.10.008_bib0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/IPC.0b013e31827ce847","article-title":"Treatment of vancomycin-resistant enterococcal bacteremia in an observational cohort of neutropenic oncology patients daptomycin versus linezolid","volume":"21","author":"Barbour","year":"2013","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jgar.2019.10.008_bib0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/IPC.0b013e31822b7f6e","article-title":"Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia","volume":"19","author":"Bio","year":"2011","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jgar.2019.10.008_bib0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02216-16","article-title":"Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant enterococcus faecium bacteremia","volume":"61","author":"Britt","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jmii.2011.11.005","article-title":"Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan","volume":"45","author":"Chou","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.008_bib0100","doi-asserted-by":"crossref","first-page":"890.e1","DOI":"10.1016\/j.cmi.2016.07.018","article-title":"Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose","volume":"22","author":"Chuang","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2019.10.008_bib0105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.clinthera.2010.09.008","article-title":"Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study","volume":"32","author":"Crank","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2019.10.008_bib0110","article-title":"Daptomycin (D) compared to linezolid (L) for primary treatment of vancomycin-resistant enterococcal bacteremia (VREB)","author":"Dubrovskaya","year":"2008","journal-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jgar.2019.10.008_bib0115","article-title":"Daptomycin and linezolid in the treatment of vancomycin-resistant enterococcal bacteremia: a retrospective analysis of treatment outcomes","author":"El-Lababidi","year":"2007","journal-title":"45th Annual Meeting of Infectious Disease Society of America"},{"key":"10.1016\/j.jgar.2019.10.008_bib0120","article-title":"Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia","author":"Furuya","year":"2005","journal-title":"45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jgar.2019.10.008_bib0125","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.02943-14","article-title":"Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci","volume":"58","author":"Hayakawa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0130","first-page":"1969","article-title":"Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients","volume":"19","author":"Kraft","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jgar.2019.10.008_bib0135","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/jac\/dks181","article-title":"Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis","volume":"67","author":"Lu","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/dkp154","article-title":"Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?","volume":"64","author":"Mave","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0145","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1017\/S0950268810002475","article-title":"Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents","volume":"139","author":"McKinnell","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2019.10.008_bib0150","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw172.1567","article-title":"Linezolid versus daptomycin in the treatment of vancomycin-resistant enterococcal bloodstream infection (VRE-BSI) at a transplant center","author":"Mckinnell","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0155","article-title":"Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia","volume":"6","author":"Narayanan","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0160","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1078155214556523","article-title":"Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus","volume":"22","author":"Patel","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgar.2019.10.008_bib0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IPC.0000000000000482","article-title":"Comparison of daptomycin and linezolid in the treatment of vancomycin-resistant enterococcus faecium in the absence of endocarditis","volume":"25","author":"Suleyman","year":"2017","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jgar.2019.10.008_bib0170","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv133.550","article-title":"Efficacy and safety of high-dose daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcus (VRE) bacteremias: a retrospective study","author":"Truong","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jhm.994","article-title":"Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin","volume":"7","author":"Twilla","year":"2012","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jgar.2019.10.008_bib0180","article-title":"Linezolid versus high-dose daptomycin for vancomycin-resistant enterococcal blood stream infections","author":"Wenzler","year":"2015","journal-title":"25th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"10.1016\/j.jgar.2019.10.008_bib0185","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","article-title":"Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia","volume":"51","author":"Ye","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2019.10.008_bib0190","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ444","article-title":"Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients","volume":"61","author":"Britt","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0200","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200767100-00008","article-title":"Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia","volume":"67","author":"Hair","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2019.10.008_bib0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jgar.2015.04.003","article-title":"Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009\u20132013)","volume":"3","author":"Sader","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2019.10.008_bib0210","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1128\/AAC.06439-11","article-title":"Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic\/pharmacodynamic model with simulated endocardial vegetations","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.008_bib0215","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clinthera.2016.09.011","article-title":"Vancomycin-resistant enterococcal bloodstream infections in hematopoietic stem cell transplant recipients and patients with hematologic malignancies: impact of daptomycin MICs of 3 to 4mg\/L","volume":"38","author":"Chong","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2019.10.008_bib0220","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of minimum inhibitory concentration in clinical outcomes of enterococcus faecium bacteremia treated with daptomycin: is it time to change the breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0225","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0230","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Andrew Seaton","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2019.10.008_bib0240","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin \u00ae Outcomes Registry and Experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jgar.2019.10.008_bib0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.008_bib0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/1469-0691.12497","article-title":"Systematic reviews and meta-analyses in infectious diseases: topics that merit special attention","volume":"20","author":"Leibovici","year":"2014","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:53:54Z","timestamp":1761990834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519302620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":50,"alternative-id":["S2213716519302620"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.10.008","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}